Aduhelm: an approval date was not an access-ready launch

Clarus Biotech Review

The 2021–2024 sequence connects authorization, pricing, coverage, and the cost of stopping.

Aduhelm is a launch-readiness case in which different milestones moved in different directions. It received FDA accelerated approval in June 2021. The later commercial and coverage record shows why the date of authorization cannot stand in for the complete patient-start pathway. [1]

## Pricing changed before the access question was settled

In December 2021, Biogen announced an approximately 50% reduction in wholesale acquisition cost, effective January 1, 2022. The announcement described an average annual cost of $28,200 for a patient of the specified weight. This was a list-price measure, not actual payer spending or total treatment-episode cost. [2]

## Coverage imposed a separate evidence gate

CMS's April 7, 2022 national policy limited coverage for accelerated-approved anti-amyloid antibodies in this class to FDA- or NIH-approved clinical trials. The policy treated products with evidence supporting traditional approval differently. For launch planning, that distinction meant the authorization route and the reimbursement pathway could not be modeled as one automatic step. [3]

## The exit carried its own financial result

On January 31, 2024, Biogen announced discontinuation of Aduhelm development and commercialization and termination of ENVISION. It reported an approximately $60 million close-out charge recorded in fourth-quarter 2023. The company stated the decision was not related to safety or efficacy concerns and described a portfolio review and inability to secure external partners or financing. Do not replace that explanation with an unsupported single-cause claim. [1]

## The readiness register should change the spending plan

Before committing a field organization or capacity, connect evidence route, coverage conditions, treatment-center workflow, monitoring, and downside runway. Set spending gates around reachable patient starts and the next evidence obligation. A price reduction can address one assumption without resolving another; a launch dashboard should make that dependency visible before fixed costs expand.

Source adaptation: the BioClarus launch-readiness framework supplies the sequencing lens. This historical case replaces the earlier generic discussion of upstream preparation.

Sources

https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise

https://investors.biogen.com/news-releases/news-release-details/biogen-announces-reduced-price-aduhelmr-improve-access-patients

https://www.cms.gov/newsroom/press-releases/cms-finalizes-medicare-coverage-policy-monoclonal-antibodies-directed-against-amyloid-treatment

Original article: https://www.clarusreview.bio/articles/launch-readiness-before-phase-3